Critical Review: Amarantus Bioscience (OTCMKTS:AMBS) and Clover Health Investments (NASDAQ:CLOV)

Clover Health Investments (NASDAQ:CLOV) and Amarantus Bioscience (OTCMKTS:AMBS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Insider and Institutional Ownership

19.8% of Clover Health Investments shares are held by institutional investors. 23.5% of Clover Health Investments shares are held by insiders. Comparatively, 10.3% of Amarantus Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Clover Health Investments and Amarantus Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clover Health Investments	$1.92 billion	1.17	-$85.55 million	($0.05)	-84.60
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A

Amarantus Bioscience has lower revenue, but higher earnings than Clover Health Investments.

Risk and Volatility

Clover Health Investments has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Profitability

This table compares Clover Health Investments and Amarantus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clover Health Investments	-0.74%	-4.20%	-2.28%
Amarantus Bioscience	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings for Clover Health Investments and Amarantus Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clover Health Investments	1	3	1	0	2.00
Amarantus Bioscience	0	0	0	0	0.00

Clover Health Investments presently has a consensus price target of $4.33, suggesting a potential upside of 2.44%. Given Clover Health Investments’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Clover Health Investments is more favorable than Amarantus Bioscience.

Summary

Clover Health Investments beats Amarantus Bioscience on 7 of the 10 factors compared between the two stocks.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.